These results are similar to those of subgroup analyses of elderly patients in phase III comparative studies and indicate the high efficacy of EGFR-TKI as treatment for EGFR mutation-positive lung cancer, even in elderly patients with poor PS. This evidence concerns the gene EGFR and lung cancer.